science

Tafasitamab

Tafasitamab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tafasitamab rather than just read about it. In short: Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.

Key takeaways

Tafasitamab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tafasitamab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tafasitamab from memory before moving on to harder problems.

Reference excerpt

Tafasitamab, sold under the brand name Monjuvi, is an anti-cancer medication used in combination with lenalidomide for the treatment of adults with diffuse large B-cell lymphoma; or, when used in combination with lenalidomide and rituximab, for the treatment of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby. The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite. Tafasitamab was approved for medical use in the United States in July 2020, and in the European Union in August 2021. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical uses Tafasitamab, in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. In the EU, tafasitamab (Minjuvi) is indicated in combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant. In June 2025, the US Food and Drug Administration (FDA) expanded the indication for tafasitamab, in combination with lenalidomide and rituximab, for adults with relapsed or refractory follicular lymphoma.

History The US Food and Drug Administration (FDA) approved tafasitamab based primarily on evidence from one clinical trial (NCT02399085) of 81 participants 42 to 86 years old. Participants in the trial had lymphoma that relapsed or did not improve after prior treatments. The trial was conducted at 35 sites in the United States and Europe. At first, participants received tafasitamab in combination with lenalidomide and later tafasitamab alone following a specific schedule during each 28-day treatment cycle. Treatment continued until disease progression or unacceptable side effects. Both participants and health care providers knew which treatment had been given. The benefit of tafasitamab was evaluated by measuring how many participants had a complete or partial tumor shrinkage and how long that response lasted (called best overall response rate). Efficacy for the treatment of follicular lymphoma was evaluated in inMIND, a double-blind, placebo-controlled trial (NCT04680052) randomizing 548 participants with relapsed or refractory follicular lymphoma to receive tafasitamab or placebo with lenalidomide and rituximab. Participants had received a median of one prior line of systemic therapy; 25% and 20% had two and three or more prior lines, respectively. The FDA granted the application for tafasitamab priority review and orphan drug designations for follicular lymphoma.

Society and culture

Names Tafasitamab is the international nonproprietary name (INN). Tafasitamab is sold under the brand names Monjuvi and Minjuvi.

References

External links Clinical trial number NCT02399085 for "A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (L-MIND)" at ClinicalTrials.gov Clinical trial number NCT04680052 for "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Tafasitamab

Start with the simplest possible case. Write down what Tafasitamab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tafasitamab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tafasitamab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tafasitamab

In research: Tafasitamab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tafasitamab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tafasitamab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Monoclonal antibodies for tumors, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Tafasitamab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tafasitamab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tafasitamab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tafasitamab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tafasitamab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tafasitamab in simple terms?

Why does Tafasitamab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tafasitamab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tafasitamab.